Trials / Completed
CompletedNCT00185588
Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
A Phase 1-2 Study of the VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 <Vatalanib> and Gemcitabine in Patients With Advanced Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- George Albert Fisher · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the optimal safe and tolerable dose of gemcitabine in combination with once daily or twice daily dose of PTK/ZK in patients with unresectable pancreatic cancer. The Phase II part of this study planned to determine the antitumor activity of this regimen and its effectiveness of preventing tumor growth and spread.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vatalanib | Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours |
| DRUG | Gemcitabine | 850 mg/m2 |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2009-01-01
- Completion
- 2009-12-01
- First posted
- 2005-09-16
- Last updated
- 2014-09-15
- Results posted
- 2014-09-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00185588. Inclusion in this directory is not an endorsement.